Rezolute, Inc. (RZLT) Financial Analysis & Valuation | Quarter Chart
Rezolute, Inc. (RZLT)
RZLTPrice: $2.6
Fair Value: 🔒
🔒score
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for ... more
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for me... more
Description
Shares
| Market Cap | $248.34M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Nevan Charles Elam |
| IPO Date | 2013-01-14 | CAGR | — |
| Employees | 64 | Website | www.rezolutebio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
RZLT chart loading...
Fundamentals
Technicals
| Enterprise Value | $235.55M | P/E Ratio | -2.82 |
| Forward P/E | -5.06 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-0.92 | EPS Growth 1Y | -27.34% |
| EPS Growth 3Y | -51.56% | EPS Growth 5Y | -71.12% |
| Revenue Growth 1Y | -20.69% | Gross Margin | -0.5% |
| Operating Margin | -1332.3% | Profit Margin | -1677.91% |
| ROE | -0.63% | ROA | -0.49% |
| ROCE | -0.41% | Current Ratio | 15.15 |
| Quick Ratio | 15.15 | Cash Ratio | 0.89 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 3.63 | Piotroski Score | 2 |